BACKGROUND: Carboetomidate is an etomidate derivative that produces hypnosis without inhibiting adrenal corticosteroid synthesis. Similar to etomidate, carboetomidate modulates ␥-aminobutyric acid type A receptors, but its effects on other ion channel targets of general anesthetics are unknown. METHODS: We compared etomidate and carboetomidate effects on human N-methyl-D-aspartate receptors or neuronal nicotinic acetylcholine receptors (nnAChRs) expressed in Xenopus oocytes, using 2-microelectrode voltage clamp electrophysiology. RESULTS: Etomidate did not affect either type of receptor at clinically relevant concentrations, whereas carboetomidate concentrations near 50% effective concentration for anesthesia significantly inhibited nnAChRs. CONCLUSIONS: Compared with etomidate, carboetomidate's higher hydrophobicity is associated with greater inhibition of nnAChRs.
C arboetomidate is a new sedative hypnotic pyrrole with a molecular structure similar to etomidate. 1 The replacement of an imidazole nitrogen on etomidate with carbon increases hydrophobicity, 2 while modestly reducing hypnotic potency and eliminating inhibition of adrenocortical steroid synthesis. Etomidate is remarkably selective for ion channel targets, acting almost exclusively at ␥-aminobutyric acid type A (GABA A ) receptors containing ␤2 or ␤3 subunits. 3, 4 Carboetomidate also modulates ␤2/3 GABA A receptors, 1 but its effects on other ion channel targets of general anesthetics remain unexplored.
METHODS Animals
Female Xenopus laevis frogs were housed in a veterinariansupervised facility and used with approval from the Massachusetts General Hospital Subcommittee on Research Animal Care. Methods for Xenopus oocyte harvest and culture have been described previously. 5 Ion Channel Expression DNA plasmids encoding human N-methyl-d-aspartate (NMDA) receptor (NMDAR) subunits NR1B and NR2A were obtained from Prof. Steven Treistman (University of Massachusetts Medical School, Worcester, MA). Plasmids encoding the human neuronal nicotinic acetylcholine receptor (nnAChR) subunits ␣4 and ␤2 were obtained from Prof. James Patrick (Salk Institute, La Jolla, CA). Capped messenger RNAs (mRNAs) were transcribed in vitro using commercial kits (Ambion, Austin, TX). Oocytes were injected with 1:1 mRNA mixtures of NR1B ϩ NR2A or ␣4 ϩ ␤2, and incubated in ND96 solution (in mM: 96 NaCl, 4 KCl, CaCl 2 1.8, MgCl 2 1.0, HEPES 5, and EGTA 1.0, pH 7.5) supplemented with 100 g/mL each of amikacin and ciprofloxacin 6 for 48 to 96 hours before electrophysiology.
Drugs and Chemicals
Etomidate (Bedford Laboratories, Bedford, OH) was formulated in 35% propylene glycol/water (v/v). Carboetomidate (Aberjona Laboratories, Beverly, MA) was prepared as a 10 mM stock in dimethyl sulfoxide. Anesthetic stock solutions were diluted in appropriate electrophysiology buffer for each type of channel. Propylene glycol or dimethyl sulfoxide, at the highest concentrations present in experiments, produced no effects on ion channels. Extra virgin olive oil (lot L-134-AB) was purchased from World Finer Foods, Inc. (Bloomfield, NJ). Acetylcholine chloride, NMDA, glycine, antibiotics, and other buffers and salts were purchased from Sigma-Aldrich (St. Louis, MO).
Partition Coefficients
Partition coefficients between olive oil and aqueous buffer (Tris 10 mM, pH 7.4) were assessed at 20°C to 22°C using published methods based on quantitative high-performance liquid chromatography. 2 
Electrophysiology
Conditions for studying NMDARs and nnAChRs using 2-microelectrode electrophysiology have been described previously. 5, 7 Voltage-clamped currents (20°C-22°C) were digitized (100 Hz), recorded, and analyzed offline to evaluate baseline-corrected peaks. In nnAChR experiments, oocytes were preexposed to anesthetic for 30 to 90 seconds before activation with 10 M acetylcholine in the presence Reprints will not be available from the authors. of anesthetic. Peak currents were normalized to responses measured in the same cell without anesthetic. For NMDAR experiments, receptors were first activated by agonists (100 M NMDA plus 10 M glycine) and then exposed to agonists plus anesthetic for a period of time before returning to agonists alone. Anesthetic effects were assessed by comparing currents averaged over a 10-second epoch immediately before the addition of drug to a 10-second epoch after full effect was evident.
Data Analysis
Normalized responses at each anesthetic concentration were averaged for n Ն5 oocytes, from at least 2 frogs, and are reported as mean Ϯ SD. Concentration-dependent data were fitted with logistic (Hill) equations of the form: NMDARs are thought to contribute to immobility for various anesthetic drugs. 8 Our initial electrophysiological studies examined the effect of high concentrations of anesthetics on NR1B/NR2A NMDARs (Fig. 1 ). Etomidate at 100 M produced 15% Ϯ 8.9% (mean Ϯ SD; n ϭ 5) inhibition of NMDARs, consistent with previous reports. 9, 10 Nearsaturated solutions of carboetomidate in aqueous buffer (40 M) inhibited NMDARs by 2.1% Ϯ 0.60% (n ϭ 5). Given that the concentrations tested are approximately 8 times the carboetomidate 50% effective concentration (EC 50 ) (5.4 M) and 43 times the etomidate EC 50 (2.3 M) for loss of righting reflexes (LORRs) in tadpoles, we did not further examine the concentration-dependent effects of either drug in NMDARs.
Neuronal nAChRs apparently contribute little to immobility, 11, 12 but may partially mediate amnesia and other anesthetic actions. In oocytes expressing ␣4␤2 nnAChRs, we observed significant concentration-dependent inhibition of ACh-activated currents by carboetomidate (Fig. 2) . The carboetomidate IC 50 for this effect was 13 M (95% confidence interval: 9.9 -18 M; n ϭ 5). Etomidate inhibited nnAChRs with an IC 50 of 160 M (95% confidence interval: 113-229 M; n ϭ 6). At their respective EC 50 values for LORR in tadpoles, 1 our results predict Ͼ25% inhibition of ␣4␤2 nnAChRs by carboetomidate and Ͻ5% inhibition by etomidate.
CONCLUSIONS
Our major new finding is that carboetomidate, at concentrations near its EC 50 for LORR in animals, inhibits ␣4␤2 nnAChR channels, but not NR1B/NR2A NMDARs. In agreement with prior studies, 9, 10 we also observed that both human NMDARs and nnAChRs are insensitive to etomidate at clinically relevant concentrations. We measured oil/water partition coefficients for carboetomidate and etomidate, and found changes in comparison to n-octanol/water partition coefficients. 2 Interestingly, etomidate partitions from water more into olive oil than into n-octanol, whereas carboetomidate partitions more into n-octanol than into oil. As a result, the carboetomidate/etomidate ratio of partition coefficients in olive oil is 3.7, whereas in n-octanol this ratio is 18.8. The inhibitory potency of halogenated ether anesthetics and nonimmobilizers at ␣4␤2 nnAChRs is strongly dependent on the olive oil/water partition coefficient. 5 Both etomidate and carboetomidate seem to follow this correlation, because inhibition of nnAChRs by carboetomidate is 12-fold more potent than etomidate. Thus, perhaps because carboetomidate has greater hydrophobicity but lower anesthetic potency than etomidate, equi-effective anesthetic concentrations of carboetomidate inhibit nnAChRs far more than etomidate.
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